Author
Reading time
Published
Categories
Neumirna Therapeutics, a Denmark-based biotech company focused on RNA therapies for neurological disorders, has raised €20M in the initial closing of its Series A funding round. The round was co-led by Invivo Partners and Angelini Ventures, with Innovestor Life Science Fund proud to continue its role as an investor after initially backing Neumirna in its seed round. The round also saw participation from private investors.
“We made our first investment in Neumirna two years ago and have worked closely with the company to systematically build it hands-on. It is extremely rewarding to now join this Series A syndicate with two excellent new investors who bring additional expertise and support to Neumirna’s mission,” Milla Koistinaho, Partner at Innovestor Life Science Fund, says.
Neumirna’s pioneering drug discovery platform enables the development of RNA-based therapies targeting previously intractable neurological conditions. Their lead therapeutic candidate, NMT.001, targets drug-resistant epilepsy (DRE), addressing a critical unmet need for millions of patients. With promising preclinical results, this funding will enable Neumirna to advance NMT.001 through the next stages of development, expand its R&D capabilities, and move closer to delivering impactful therapies for neurological disorders.
“This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001,” says Professor Janine Erler, CEO of Neumirna Therapeutics. “We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.”
Neumirna’s RNA therapies have the potential to transform treatment options for patients living with challenging neurological disorders, and we are proud to play a role in their journey. We look forward to seeing Neumirna continue to deliver on its ambitious vision.